Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC, SOX, and Tislelizumab in Gastric Cancer with Peritoneal Metastasis
NCT06685887Phase 2Recruiting
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC). Started Feb 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06685887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685887.